MDT vs PHG: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of October 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. MDT and PHG share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined MDT and PHG exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Medtronic is one of the largest medical device companies in the world, designing, manufacturing, and selling therapies and devices across a broad range of chronic and acute conditions. Its business spans three main areas after October 2026: Cardiovascular (pacemakers, defibrillators, heart valves, and cardiac ablation), Neuroscience (spine implants, neuromodulation for pain and movement disorders, and surgical navigation), and Medical Surgical (surgical stapling, energy devices, and a growing robotic-surgery platform). Its former Diabetes unit (insulin pumps and continuous glucose monitoring) was carved out as MiniMed, which listed on Nasdaq under MMED; on October 15, 2026 Medtronic exchanged its remaining 252.8 million MiniMed shares for Medtronic shares in an exchange offer that was 5.4 times subscribed, so it no longer owns any of MiniMed. The company sells primarily to hospitals, surgeons, and health systems, generating durable, recurring demand tied to procedure volumes and chronic-disease management. Medtronic's scale gives it deep relationships with providers, a large installed base of devices, and the resources to fund extensive R&D and acquisitions. Growth depends on new product cycles, pipeline approvals, and global expansion, especially in emerging markets. Founded in 1949 and headquartered in Ireland for tax purposes (operationally rooted in Minnesota), Medtronic is a large-cap, dividend-growing medical-technology company tied to long-term healthcare demand and aging demographics, with trailing revenue of about $37.5 billion as of October 2026.

Full MDT guide

Koninklijke Philips N.V. (Royal Philips) is a Netherlands-based health-technology company that generated roughly EUR 17.8 billion (about $19 billion) in 2025 sales across three segments: Diagnosis and Treatment (imaging systems, image-guided therapy, ultrasound), Connected Care (patient monitoring, hospital informatics, and its Respironics sleep and respiratory business), and Personal Health (electric shavers, toothbrushes, and mother-and-child care). US investors most commonly access it through the PHG American Depositary Receipt on the NYSE, which represents ordinary shares that also trade in Amsterdam; the ADR structure means currency moves between the euro and the dollar affect the quoted price and the dividend.

Full PHG guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• MDT drivers: Diversified device portfolio; Innovation pipeline and new product cycles.
• PHG drivers: Margin recovery and cost discipline; Order intake and installed-base momentum.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: Medtronic has at times delivered sluggish organic growth, raising concerns that its scale slows innovation relative to nimbler competitors like Boston Scientific and Edwards Lifesciences. For PHG, china remains a drag, hurt by industry-wide anti-corruption measures, subdued demand, and share losses in imaging, and a single soft quarter there has moved the stock sharply in the past.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick MDT if you believe its drivers more; PHG if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the MDT and PHG guides.

MDT. At about $95 on October 16, 2026, Medtronic trades near 15 times forward earnings, a moderate multiple next to faster-growing medtech peers, while the GAAP trailing P/E of about 23x includes acquisition amortization. The 25 analysts tracked by Yahoo Finance hold a mean target near $104. The next report, expected around November 17, 2026, will be the first read on the company after the MiniMed exit, with consensus at about $1.33 of EPS on $9.5 billion of revenue.

PHG. At $26.00 on October 16, 2026, Philips trades around 19 times trailing and 14 times forward earnings, about 1.4 times sales, and near 2 times book value, cheaper than a year ago even though profits have recovered. The market is weighing flat sales and a softer second half (consensus Q3 EPS 0.36, down about 13%) against margin gains and fading legal risk. Figures are approximate, reported in euros, and converted to dollars at prevailing rates for the ADR.

Headline figures (approximate, October 2026): MDT shows revenue (ttm) ~$37.5 billion, up ~14% year over year in the July 2026 quarter, margins ~65% gross, ~19% operating, ~14% net, net income (ttm) ~$5.2 billion, eps ~$4.07 GAAP trailing; ~$6.41 forward estimate; PHG shows revenue (ttm) ~EUR 17.7B (2025: ~EUR 17.8B); +0.5% yoy in Q2 2026, net income (ttm) ~EUR 1.1B (2025: ~EUR 897M), eps (q2 2026 vs estimate) 0.56 vs ~0.37, operating margin (ttm) ~14%.

MDT and PHG are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined MDT and PHG exposure against your real portfolio. It is not an investment adviser.